Immediate Infusion Reaction to Intravenous Risankizumab-rzaa but Subsequent Tolerance to Subcutaneous Risankizumab-rzaa.

IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY

ACG Case Reports Journal Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI:10.14309/crj.0000000000001546

David Choi, Benjamin McDonald, David T Rubin

引用次数: 0

Abstract

Risankizumab-rzaa (RZA) is a fully human immunoglobulin G monoclonal antibody (Mab) which has fewer immunogenic concerns compared with chimeric Mabs. The pivotal trials of RZA found no significant differences in infusion reactions between drug and placebo. This case illustrates successful transition to subcutaneous RZA following a serious hypersensitivity reaction to intravenous RZA.

查看原文本刊更多论文

静脉注射 Risankizumab-rzaa 后立即出现输注反应，但随后对皮下注射 Risankizumab-rzaa 产生耐受性。

利桑珠单抗-rzaa（RZA）是一种全人源免疫球蛋白 G 单克隆抗体（Mab），与嵌合型 Mab 相比，其免疫原性问题较少。RZA 的关键试验发现，该药物与安慰剂的输注反应无明显差异。本病例说明了在静脉注射 RZA 后出现严重超敏反应后成功过渡到皮下注射 RZA 的情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACG Case Reports Journal GASTROENTEROLOGY & HEPATOLOGY-

自引率

14.30%

发文量

170

审稿时长

12 weeks

期刊介绍： ACG Case Reports Journal is a peer-reviewed, open-access publication that provides GI and hepatology fellows, private practice clinicians, and other healthcare providers an opportunity to share interesting case reports with their peers and with leaders in the field. ACG Case Reports Journal publishes case reports, images, videos and letters to the editor in all topics of gastroenterology and hepatology, including: Biliary Colon Endoscopy Esophagus Functional Bowel Disorders Inflammatory Bowel Disease Liver Nutrition and Obesity Pancreas Pathology Pediatric Small Bowel Stomach.